Suppr超能文献

澳大利亚结节性硬化症“未发现突变”队列的深度测序和表型分析。

Deep Sequencing and Phenotyping in an Australian Tuberous Sclerosis Complex "No Mutations Identified" Cohort.

机构信息

Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Tuberous Sclerosis Management Clinic, Sydney Children's Hospital, Randwick, New South Wales, Australia.

出版信息

Mol Genet Genomic Med. 2024 Oct;12(10):e70017. doi: 10.1002/mgg3.70017.

Abstract

UNLABELLED

Tuberous sclerosis complex (TSC) is a variable multisystem disorder. The "no mutations identified" (NMI) group are reportedly phenotypically milder than those with an identified molecular cause, and often have mosaic or intronic variants not detected by standard sequencing methods.

METHODS

We describe the phenotypes in an Australian TSC NMI group (n = 18) and a molecular testing strategy implementable in a diagnostic laboratory. Massively parallel sequencing (MPS) of the whole genomic regions of TSC1 and TSC2 was performed using DNA extracted from multiple tissue samples per participant.

RESULTS

Our study showed that the phenotype in TSC NMI individuals can be similar to those with heterozygous, particularly TSC1, variants. Although neurodevelopmental outcomes can be less severe, the number of organ systems involved was similar to the non-mosaic groups. A diagnostic yield of 72% (13/18) was achieved, with the majority (10/13) being mosaic variants and the remainder heterozygous variants missed on previous testing.

CONCLUSION

Testing DNA from multiple tissue samples allowed for validation of otherwise discarded low-level mosaic variants and detection of mosaic variants by MPS without excessive cost or the need for specialised techniques. Implementing this approach in a diagnostic setting is viable and allows optimal clinical care of patients with NMI TSC.

摘要

目的

描述一组澳大利亚结节性硬化症复合征(TSC)无突变(NMI)患者的表型,并提出一种适用于诊断实验室的分子检测策略。

方法

对每位参与者的多个组织样本提取 DNA,采用全基因组区域的 MPS 对 TSC1 和 TSC2 的整个基因组进行测序。

结果

我们的研究表明,NMI 个体的表型可能与杂合子,尤其是 TSC1 变异体相似。尽管神经发育结局可能不那么严重,但受累器官系统的数量与非嵌合组相似。获得了 72%(13/18)的诊断率,其中大多数(10/13)为嵌合变体,其余为先前检测中遗漏的杂合变体。

结论

从多个组织样本中检测 DNA 可验证原本被丢弃的低水平嵌合变体,并通过 MPS 检测到嵌合变体,而不会增加成本或需要专门技术。在诊断环境中实施这种方法是可行的,并能为 NMI TSC 患者提供最佳的临床护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aae/11443604/c7ec6862d02c/MGG3-12-e70017-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验